R&D

Moderna, AstraZeneca, R&D, mRNA vaccine, vascular endothelial growth factor

Moderna axes four programs, including two former AstraZeneca collaborations

Anika Sharma

Moderna, following its recent phase 3 success with an mRNA flu vaccine, has made the decision to remove four clinical ...